Small Cell Lung Cancer — Expanded Access Programs
Overview
Right2Hope maintains a directory of 50 expanded access programs, clinical trials, and compassionate use pathways listed for Small Cell Lung Cancer. Each entry below was sourced from sponsor disclosures and public clinical-trial registries. Use this hub to understand the breadth of ongoing research, identify sponsors with small cell lung cancer programs, and link out to specific protocols for eligibility, contact, and request details. Of these, 20 programs are currently active or recruiting, with the remaining 30 in other lifecycle stages. Sponsors actively running programs in this area include Amgen, AbbVie, Washington University School of Medicine, AstraZeneca, Fox Chase Cancer Center, and others.
By recruiting status
Snapshot of where every Small Cell Lung Cancer program currently sits in its lifecycle.
- Active / Recruiting20
- Inactive30
Top sponsors
Organisations running the most Small Cell Lung Cancer programs in the directory.
- Amgen4 programs
- AbbVie3 programs
- Washington University School of Medicine3 programs
- AstraZeneca2 programs
- Fox Chase Cancer Center2 programs
- Memorial Sloan Kettering Cancer Center2 programs
- Merck Sharp & Dohme LLC2 programs
- National Cancer Institute (NCI)2 programs
- Pfizer2 programs
- Advenchen Pharmaceuticals, LLC.1 program
Small Cell Lung Cancer programs (50)
Sorted by recruiting status, then alphabetically by program name. Click any program to view eligibility, locations, and sponsor contact details.
- Phase III Study of Maintenance Treatment with Lurbinectedin and Atezolizumab vs. Atezolizumab Alone for Extensive-Stage Small-Cell Lung Cancer — Hoffmann-La Roche
- Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide with Durvalumab, Carboplatin, and Etoposide for First-line Treatment of Extensive Stage Small-Cell Lung Cancer — Amgen
- Study of IDE849 for Patients with DLL3 Expressing Tumors, Including Small Cell Lung Cancer — IDEAYA Biosciences
- Study Comparing ZL-1310 to Other Treatments for Relapsed Small Cell Lung Cancer — Zai Lab (Shanghai) Co., Ltd.
- Study on ABBV-706 Compared to Standard Treatment for Adults with Relapsed or Refractory Small Cell Lung Cancer — AbbVie
- Study on ABBV-706 and Atezolizumab Compared to Standard Treatment for Newly Diagnosed Extensive Stage Small Cell Lung Cancer — AbbVie
- Study on the Safety and Effectiveness of Gocatamig and Ifinatamab Deruxtecan for Treating Relapsed or Resistant Extensive-Stage Small Cell Lung Cancer — Merck Sharp & Dohme LLC
- Study on AL3818 and Nivolumab for Treating Advanced Solid Tumors — Sarcoma Oncology Research Center, LLC
- Access Program for ABBV-706 Before Official Approval — AbbVie
- Study on Ipilimumab and Nivolumab for Recurrent Extensive Stage Small Cell Lung Cancer After Platinum-based Chemotherapy — Yale University
- Study on PET/CT Imaging for Small Cell Lung Cancer Using 89Zr-DFO-SC16.56 — Memorial Sloan Kettering Cancer Center
- Study on PF-07104091 as a Single Treatment and in Combination for Advanced Cancers — Pfizer
- Study on How Genetic Differences Affect Etoposide Treatment in Small Cell Lung Cancer — Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
- Phase 2 Study of Fingolimod for Lung Cancer Treatment — Medical University of South Carolina
- Study on Chemotherapy and Radiation with Pembrolizumab, Followed by Pembrolizumab and Olaparib, for Newly Diagnosed Limited-Stage Small Cell Lung Cancer — Merck Sharp & Dohme LLC
- Study on Irinotecan and Cirtuvivint for Treating Small Cell Lung Cancer (SLICK Trial) — Washington University School of Medicine
- Study on AZD2811 and Durvalumab for Treating Extensive Stage Small-Cell Lung Cancer — AstraZeneca
- Study on Durvalumab and Tremelimumab for Limited Stage Small-Cell Lung Cancer After Chemoradiation — AstraZeneca
- Study of Onvansertib for Treating Relapsed Small Cell Lung Cancer — Taofeek Owonikoko
- Study on PF-08634404 with Chemotherapy for Adults with Transformed Small Cell Lung Cancer — Pfizer
- Expanded Access Program for Lurbinectedin in Previously Treated Small Cell Lung Cancer in the USA — Jazz Pharmaceuticals
- Study on MK-6070 for Advanced Cancers with DLL3 Expression — Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Study on Alisertib for Patients with Extensive Stage Small Cell Lung Cancer — Puma Biotechnology, Inc.
- Study Comparing Ifinatamab Deruxtecan to Doctor's Choice Treatment for Relapsed Small Cell Lung Cancer — Daiichi Sankyo
- Study on Stereotactic Radiosurgery for Lung Cancer That Has Spread to the Brain — Memorial Sloan Kettering Cancer Center
- Study on ADI-PEG 20 with Gemcitabine and Docetaxel for Lung Cancer After Initial Treatment Stops Working — Washington University School of Medicine
- Chemotherapy in Patients With Relapsed Small Cell Lung Cancer in Combination With Allopurinol and MycoPhenolate (CLAMP Trial) — Washington University School of Medicine
- Chiauranib for Advanced Solid Tumors and Relapsed/Refractory Small Cell Lung Cancer — Chipscreen Biosciences, Ltd.
- Study on Reduced Dose Chemotherapy for Lung Cancer Patients with Other Health Conditions — Fox Chase Cancer Center
- Study on Durvalumab and Radiation Therapy for Treating Extensive-Stage Small Cell Lung Cancer (DARES) — University of Chicago
- Access to Trilaciclib for Patients Undergoing Chemotherapy for Small Cell Lung Cancer — G1 Therapeutics, Inc.
- Study on Iadademstat and Paclitaxel for Treating Relapsed or Hard-to-Treat Small Cell Lung Cancer and High-Grade Neuroendocrine Tumors — Fox Chase Cancer Center
- Study on IMP4297 and Temozolomide for Patients with Advanced Solid Tumors and Small Cell Lung Cancer — Impact Therapeutics, Inc.
- Liver-Targeted Radiation and Chemo-Immunotherapy for Advanced Small Cell Lung Cancer — Brian Henick, MD
- Study on M7824 and Topotecan or Temozolomide for Treating Relapsed Small Cell Lung Cancer — National Cancer Institute (NCI)
- Study on Monalizumab and Durvalumab with Chemotherapy for First-line Treatment of Extensive Stage Small Cell Lung Cancer — Hirva Mamdani
- Phase 2 Study on the Safety and Effectiveness of AL8326 for Second-Line Treatment in Small Cell Lung Cancer — Advenchen Pharmaceuticals, LLC.
- Study on New Treatment for Advanced Solid Tumors Resistant to Standard Therapies — Klus Pharma Inc.
- Study on Combination Immunotherapies for Patients Previously Treated with Immune Checkpoint Inhibitors — ImmunityBio, Inc.
- Study on the Safety and Effectiveness of NEO212 for Patients with Certain Brain Tumors or Brain Metastasis — Neonc Technologies, Inc.
- Study on the Safety and Effects of ONC-392 Alone and with Anti-PD-1 in Advanced Solid Tumors and Non-Small Cell Lung Cancer — OncoC4, Inc.
- Study on the Safety and Early Effectiveness of BNT327 with Chemotherapy for Small-Cell Lung Cancer — BioNTech SE
- Study Comparing Tarlatamab and Durvalumab with Durvalumab Alone for First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer — Amgen
- Study on Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC) — Amgen
- Study on Trilaciclib and Lurbinectedin for Small Cell Lung Cancer — UNC Lineberger Comprehensive Cancer Center
- Study on Targeted Alpha-Particle Therapy for Advanced Neuroendocrine Tumors with SSTR2 — Perspective Therapeutics
- Study on Targeted Therapy with CDK4/6 Inhibitors for Lung Cancer That Hasn't Responded to Chemotherapy — Case Comprehensive Cancer Center
- Expanded Access to Tarlatamab for Advanced Small Cell Lung Cancer — Amgen
- Study on PC14586 for Patients with Advanced Solid Tumors with a TP53 Y220C Mutation (PYNNACLE) — PMV Pharmaceuticals, Inc
- Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer — National Cancer Institute (NCI)
About this hub
Expanded access programs (sometimes called compassionate use, named-patient programs, or pre-approval access) allow patients with serious or life-threatening conditions such as Small Cell Lung Cancer to receive an investigational therapy outside of a controlled clinical trial when no comparable approved option is available. Eligibility, location, and the application process differ for each program — review the individual program pages below for sponsor contact information, inclusion criteria, and the request workflow. Right2Hope is a 501(c)(3) nonprofit and provides this directory free of charge for patients, caregivers, and treating physicians.
Looking for a different condition? Browse the full Cancer Type hub directory or search the full expanded access program catalog.